MEIP Share Price | MEI Pharma, Inc. Stock Analysis & Recommendation

Q: How big is MEI Pharma, Inc.?

Market Cap: As of Jun 18, MEI Pharma, Inc. has a market capitalization of 14.99 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, MEI Pharma, Inc. reported net sales of 0.00 million and a net profit of -31.67 million.Balance Sheet Snapshot: As of Jun'24, the company reported shareholder's funds of 33.02 million and total assets of 41.38 million.

Q: What does MEI Pharma, Inc. do?

Overview:MEI Pharma, Inc. is an oncology company focused on the clinical development of drugs and therapies for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)Market cap: USD 14.99 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.05Return on Equity: -106.26%Price to Book: 0.77Contact Details:Address: 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO CA: 92130Tel: 1 858 3697100Website: https://www.meipharma.com/

Q: Is MEI Pharma, Inc. overvalued or undervalued?

As of 8 July 2024, MEI Pharma, Inc. has moved from a very attractive valuation grade to one that does not qualify. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.74 and an EV to EBITDA ratio of 0.27, which indicate a lack of profitability and efficiency in generating earnings relative to its enterprise value. Additionally, the ROE stands at -106.26%, highlighting significant losses relative to shareholder equity.In comparison to its peers, MEI Pharma, Inc. shows a less favorable position, with Immunic, Inc. having a P/E ratio of -0.8008 and Adicet Bio, Inc. at -0.5353, suggesting that while all companies are struggling, MEI's valuation metrics are particularly concerning. The stock has underperformed significantly against the S&P 500, with a 1Y return of -10.86% compared to the index's 17.14%, and a staggering -96.17% over the last 5 years, reinforcing the notion that the company is not a viable investment at its current price.

Q: Is MEI Pharma, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for MEI Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, which supports the overall mildly bullish stance. However, the Bollinger Bands are bearish on both weekly and monthly time frames, suggesting potential downward pressure. The KST shows bullish momentum on both weekly and monthly charts, and the OBV is bullish on a monthly basis, indicating accumulation. In terms of performance, MEI Pharma has underperformed the S&P 500 across multiple periods, with a significant decline of 72.90% over the last 3 years compared to a 70.41% gain in the S&P 500. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators in the Bollinger Bands and mixed MACD signals.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

80.05 k

Shareholding (Dec 2025)

FII

5.66%

Held by 15 FIIs

DII

90.73%

Held by 5 DIIs

Promoter

0.00%

How big is MEI Pharma, Inc.?

22-Jun-2025

As of Jun 18, MEI Pharma, Inc. has a market capitalization of 14.99 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -31.67 million for the latest four quarters. The company reported shareholder's funds of 33.02 million and total assets of 41.38 million as of Jun'24.

View full answer

What does MEI Pharma, Inc. do?

22-Jun-2025

MEI Pharma, Inc. is an oncology company focused on developing cancer treatments, categorized as a micro-cap with a market cap of $14.99 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

View full answer

Who are in the management team of MEI Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of MEI Pharma, Inc. includes Dr. Christine White (Independent Chairman), Dr. Daniel Gold (President and CEO), and five Independent Directors: Mr. Charles Baltic, Dr. Kevan Clemens, Ms. Cheryl Cohen, and Mr. Frederick Driscoll.

View full answer

Is MEI Pharma, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, MEI Pharma, Inc. is considered overvalued with poor financial metrics, including a Price to Book Value of 0.74, an EV to EBITDA ratio of 0.27, a ROE of -106.26%, and significant underperformance compared to the S&P 500, making it a less attractive investment.

View full answer

Is MEI Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, MEI Pharma, Inc. has a mildly bullish technical trend, supported by daily moving averages and KST momentum, but tempered by bearish Bollinger Bands and mixed MACD signals, while significantly underperforming the S&P 500 over the past three years.

View full answer

Compare MEI Pharma, Inc. with Similar Stocks

Minerva Neurosciences, Inc.SciSparc Ltd.Societal CDMO, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 45 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.11

Return on Equity

-14.00%

Price to Book

0.56

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-31 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.67%

6 Months

-52.76%

1 Year

-48.94%

2 Years

-69.01%

3 Years

400.0%

4 Years

-90.49%

5 Years

-98.3%

MEI Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

10.57%

EBIT to Interest (avg)

-30.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.05

Sales to Capital Employed (avg)

1.43

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

33.32%

ROCE (avg)

ROE (avg)

10.25%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

-3.06

EV to EBITDA

-3.06

EV to Capital Employed

0.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-16.43%

ROE (Latest)

-14.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (3.61%)

Foreign Institutions

Held by 15 Foreign Institutions (5.66%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -755.56% vs -33.33% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-3.00",
          "chgp": "-13.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.50",
          "val2": "-0.70",
          "chgp": "-3,828.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.80",
          "val2": "-3.60",
          "chgp": "-755.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is -100.00% vs 33.81% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is -189.33% vs 155.97% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "65.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.10",
          "val2": "25.80",
          "chgp": "-166.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-10.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.90",
          "val2": "17.80",
          "chgp": "-189.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "389.60%",
          "chgp": "-38.96%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-3.00

-13.33%

Interest

0.00

Exceptional Items

-27.50

-0.70

-3,828.57%

Consolidate Net Profit

-30.80

-3.60

-755.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -755.56% vs -33.33% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

0.00

65.30

-100.00%

Operating Profit (PBDIT) excl Other Income

-17.10

25.80

-166.28%

Interest

0.00

Exceptional Items

0.00

-10.90

100.00%

Consolidate Net Profit

-15.90

17.80

-189.33%

Operating Profit Margin (Excl OI)

0.00%

389.60%

-38.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is -100.00% vs 33.81% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is -189.33% vs 155.97% in Jun 2024

All Annual Results

Company CV

About MEI Pharma, Inc.

MEI Pharma, Inc.

Pharmaceuticals & Biotechnology

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Company Coordinates

Company Details

11455 EL CAMINO REAL, SUITE 250 , SAN DIEGO CA : 92130

Tel: 1 858 3697100

https://www.meipharma.com/

Registrar Details